Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 6/20 | 0.64 |
| ▸ | ITGB1 | P05556 | 8/20 | 0.63 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.63 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.61 |
| ▸ | ITGA4 | P13612 | 4/20 | 0.59 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.59 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.58 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.58 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | ITGAV | P06756 | 3/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6428866 | 0.90 | ITGB1 (0.68) | CCR4ITGB1ITGA5CAPN1ITGA4 | |
| SCHEMBL2879401 | 0.89 | ITGB1 (0.77) | ITGB1ITGA5ITGA4ITGB7ITGA2 | |
| SCHEMBL2879404 | 0.89 | ITGB1 (0.77) | ITGB1ITGA5ITGA4ITGB7ITGA2 | |
| SCHEMBL27877728 | 0.89 | ITGB1 (0.77) | ITGB1ITGA5ITGA4ITGB7ITGA2 | |
| SCHEMBL2879402 | 0.89 | ITGB1 (0.77) | ITGB1ITGA5ITGA4ITGB7ITGA2 | |
| SCHEMBL7066228 | 0.88 | ITGB1 (0.61) | CCR4ITGB1ITGA5ITGA4ITGB7 | |
| SCHEMBL7069041 | 0.87 | ITGB1 (0.62) | CCR4ITGB1ITGA5ITGA4ITGB7 | |
| SCHEMBL4254342 | 0.86 | ITGB1 (0.77) | CCR4ITGB1ITGA5CAPN1ITGA4 | |
| SCHEMBL6374288 | 0.86 | ITGB1 (0.68) | CCR4ITGB1ITGA5CAPN1ITGA4 | |
| SCHEMBL8248907 | 0.86 | ITGB1 (0.77) | CCR4ITGB1ITGA5CAPN1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6586602-B2 | CD antigen antagonists such as N-(methanesulfonyl)-L-prolyl-L-phenylalanine and prodrugs used as antiinflammatory agents | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-07-01 | — | — | US | disclosed |
| US-20030065193-A1 | Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-04-03 | — | — | US | disclosed |
| US-6362341-B1 | ANTIINFLAMMATORY AGENTS | ATHENA NEUROSCIENCES, INC. | 2002-03-26 | — | — | US | disclosed |
| EP-1001975-A1 | BENZYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006436-A1 | BENZYL COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065193-A1 | Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, ITGB4 | CCR4 80/4885ITGB1 35/4885ITGA5 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.